GeoVax Labs, Inc. Announces the Filing of a Registration Statement for a Public Offering of Its Shares

SMYRNA, Ga., April 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities Commission for a best efforts offering to sell up to $40.0 million of units consisting of one share of common stock and a warrant to purchase 0.20 shares of common stock. The offering anticipates including shares of common stock to be sold by selling stockholders.  

The specific number of units to be offered and the price range for the offering have yet to be determined. The purpose of the offering will be to raise funds to support clinical trials of the Company's vaccines and for general business purposes.

The placement agent for the offering is Global Hunter Securities LLC. A copy of the preliminary prospectus may be obtained from Tim Monfort, Head of Equity Capital Markets, 444 Madison Ave 40th Floor, New York, NY 10022, (212) 400-4806.

This press release is being issued in accordance with Rule 134 of the Securities Act of 1933, as amended.  

A REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BUT HAS NOT YET BECOME EFFECTIVE.  THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES EFFECTIVE.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

SOURCE GeoVax Labs, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED